RSV Vaccine and History of Thyroid Cancer
Yes, patients with a history of thyroid cancer can and should receive the RSV vaccine if they are aged 60 years or older, as thyroid cancer history is not a contraindication to RSV vaccination.
Recommendation Based on Guidelines
The 2024 ASCO guideline on vaccination of adults with cancer explicitly states that patients aged 60 years and older with cancer are eligible to receive the RSV vaccine 1. This recommendation applies broadly to adults with cancer, without specific exclusions for particular cancer types including thyroid cancer.
Key Points from the Evidence:
No cancer-specific contraindications exist: The guideline does not list any specific cancer types, including thyroid cancer, as contraindications to RSV vaccination 1
Timing considerations: While the guideline notes that optimal immune responses occur when vaccines are administered immediately after cancer diagnosis and before immunosuppressive treatments, this primarily applies to vaccines requiring robust immune responses like the recombinant zoster vaccine 1
Thyroid cancer context: Most thyroid cancer patients, particularly those with differentiated thyroid cancer (papillary or follicular), are not on immunosuppressive chemotherapy regimens. They typically receive thyroid hormone suppression therapy and radioactive iodine, which do not significantly impair immune function
Clinical Implementation
For patients with thyroid cancer history:
- If aged ≥60 years: Recommend RSV vaccination
- If aged <60 years: No specific recommendation can be made based on current evidence, as data are lacking for this age group with cancer 1
- RSV vaccine can be coadministered with other seasonal immunizations per CDC guidance 1
Important Caveats:
The only scenario where caution might be warranted is if the patient has anaplastic or medullary thyroid cancer requiring active cytotoxic chemotherapy. However, even in these cases, vaccination is not contraindicated—it remains recommended, though immune responses may be suboptimal during active treatment.
Recent real-world data from patients with systemic autoimmune rheumatic diseases showed only 0.8% breakthrough infection rate among vaccinated patients, with minimal severe outcomes 2, suggesting good vaccine effectiveness even in potentially immunocompromised populations.